Third, these cohort results strengthen the results of the TANGO trial, and last but not least, it suggests a potential immunological benefit in increasing CD4+ lymphocyte count and CD4+/CD8+ ratio independently of age, sex, HIV stage, and pre-existing AIDS. The gene discussed is CD4; the disease is AIDS.